| First Author | Hogan MF | Year | 2016 |
| Journal | Endocrinology | Volume | 157 |
| Issue | 9 | Pages | 3462-8 |
| PubMed ID | 27404391 | Mgi Jnum | J:240127 |
| Mgi Id | MGI:5882455 | Doi | 10.1210/en.2016-1410 |
| Citation | Hogan MF, et al. (2016) Inhibition of Insulin-Degrading Enzyme Does Not Increase Islet Amyloid Deposition in Vitro. Endocrinology 157(9):3462-8 |
| abstractText | Islet amyloid deposition in human type 2 diabetes results in beta-cell loss. These amyloid deposits contain the unique amyloidogenic peptide human islet amyloid polypeptide (hIAPP), which is also a known substrate of the protease insulin-degrading enzyme (IDE). Whereas IDE inhibition has recently been demonstrated to improve glucose metabolism in mice, inhibiting it has also been shown to increase cell death when synthetic hIAPP is applied exogenously to a beta-cell line. Thus, we wanted to determine whether a similar deleterious effect is observed when hIAPP is endogenously produced and secreted from islets. To address this issue, we cultured hIAPP transgenic mouse islets that have the propensity to form amyloid for 48 and 144 hours in 16.7 mM glucose in the presence and absence of the IDE inhibitor 1. At neither time interval did IDE inhibition increase amyloid formation or beta-cell loss. Thus, the inhibition of IDE may represent an approach to improve glucose metabolism in human type 2 diabetes, without inducing amyloid deposition and its deleterious effects. |
